← feed

Is NCT03161015 results overdue?

Yes — results are overdue. Primary completion was 2017-05-25; the FDAAA-801 reporting deadline (2018-05-25) passed 2949 days ago and no results are posted on ClinicalTrials.gov.

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT IDNCT03161015 ↗
SponsorGlobal Blood Therapeutics (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-05-25 (ACTUAL)
Reporting deadline2018-05-25 (completion + 365d)
Days overdue2949
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 256bbd7183022416… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03161015. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →